Krystal Biotech Dirección

Dirección controles de criterios 3/4

El CEO de Krystal Biotech es Krish Krishnan , nombrado en Dec 2015, tiene una permanencia de 8.92 años. compensación anual total es $6.22M, compuesta por 11.8% salario y 88.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.43% de las acciones de la empresa, por valor de €291.47M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 6.4 años, respectivamente.

Información clave

Krish Krishnan

Chief Executive Officer (CEO)

US$6.2m

Compensación total

Porcentaje del salario del CEO	11.8%
Permanencia del CEO	8.9yrs
Participación del CEO	5.4%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	6.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Krish Krishnan en comparación con los beneficios de Krystal Biotech?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$52m
Jun 30 2024	n/a	n/a	US$106m
Mar 31 2024	n/a	n/a	US$57m
Dec 31 2023	US$6m	US$733k	US$11m
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$140m
Mar 31 2023	n/a	n/a	-US$135m
Dec 31 2022	US$3m	US$645k	-US$140m
Sep 30 2022	n/a	n/a	-US$130m
Jun 30 2022	n/a	n/a	-US$115m
Mar 31 2022	n/a	n/a	-US$104m
Dec 31 2021	US$7m	US$581k	-US$70m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$52m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$764k	US$498k	-US$32m
Sep 30 2020	n/a	n/a	-US$27m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	US$631k	US$366k	-US$19m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$16m
Mar 31 2019	n/a	n/a	-US$13m
Dec 31 2018	US$705k	US$200k	-US$11m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$10m
Dec 31 2017	US$69k	US$69k	-US$8m

Compensación vs. Mercado: La compensación total de Krish($USD6.22M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD3.51M).

Compensación vs. Ingresos: La compensación de Krish ha sido consistente con los resultados de la empresa en el último año.

CEO

Krish Krishnan (59 yo)

8.9yrs

Permanencia

US$6,223,894

Compensación

Mr. Krish S. Krishnan, M.S., M.B.A., is Founder of Krystal Biotech, Inc. since December 2015. He has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since December 2015. Mr. K...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Krish Krishnan	Founder	8.9yrs	US$6.22m	5.43% € 291.5m
Suma Krishnan	Founder	8.9yrs	US$3.84m	5.53% € 296.8m
Kathryn Romano	Executive VP & Chief Accounting Officer	4.8yrs	US$2.57m	0.045% € 2.4m
John Thomas	General Counsel & Corporate Secretary	no data	sin datos	sin datos
John Karakkal	Vice President of North American Sales & Marketing	no data	sin datos	sin datos
Christine Wilson	Head of U.S. Sales & Marketing	less than a year	sin datos	sin datos
Stephane Paquette	Vice President of Corporate Development	no data	sin datos	sin datos
Josh Suskin	Director of Human Resources & Operations	no data	sin datos	sin datos
Laurent Goux	Senior VP & GM of Europe	no data	sin datos	sin datos
David Chien	Senior Vice President of Clinical Development	2.8yrs	sin datos	sin datos
Jennifer McDonough	Senior Vice President of Patient Access	less than a year	sin datos	sin datos
Ramesh Arjunji	Senior Vice President of Global Value and Access	less than a year	sin datos	sin datos

2.8yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4KB se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Krish Krishnan	Founder	8.9yrs	US$6.22m	5.43% € 291.5m
Suma Krishnan	Founder	8.8yrs	US$3.84m	5.53% € 296.8m
Daniel Janney	Lead Independent Director	8yrs	US$610.32k	0.37% € 20.0m
Dino Rossi	Independent Director	7.4yrs	US$584.82k	0.27% € 14.7m
Julian Gangolli	Independent Director	5.7yrs	US$585.07k	sin datos
E. Sutherland	Independent Director	2.8yrs	US$570.44k	0% € 0
Christopher Mason	Independent Director	3.8yrs	US$568.32k	0% € 0
Kirti Ganorkar	Non-Employee Independent Director	7.2yrs	sin datos	sin datos
Catherine Mazzacco	Independent Director	1.7yrs	US$934.43k	0% € 0
Samuel Broder	Chairman of Scientific Advisory Board	4.8yrs	sin datos	sin datos

6.4yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 4KB se considera experimentada (6.4 años de antigüedad promedio).

Krystal Biotech Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Krystal Biotech, Inc., Annual General Meeting, May 17, 2024

Lead Independent Director recently sold €6.0m worth of stock

Founder recently sold €2.7m worth of stock

Independent Director recently sold €3.1m worth of stock

Krystal Biotech, Inc., Annual General Meeting, May 20, 2022

Krystal Biotech, Inc. Announces Board Changes

Recent updates

Krystal Biotech, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Krystal Biotech, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Krystal Biotech, Inc. to Report Q1, 2024 Results on May 06, 2024

Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Krystal Biotech, Inc., Annual General Meeting, May 17, 2024

Krystal Biotech, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Krystal Biotech Receives Permanent J-Code (J3401) for VYJUVEK®

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Krystal Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for KB408 for Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

Krystal Biotech, Inc. Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

Krystal Biotech, Inc.(NasdaqGM:KRYS) dropped from Russell Small Cap Comp Value Index

Lead Independent Director recently sold €6.0m worth of stock

Founder recently sold €2.7m worth of stock

FDA Approves New Product Utilizing Berkshire Sterile Excipient Gel to Treat 'Butterfly Children'

Krystal Biotech, Inc. announced that it expects to receive $159.999933 million in funding from Avoro Capital Advisors LLC, Redmile Group, LLC, Braidwell LP, Frazier Life Sciences Management, LP, Lighthouse Investment Partners, LLC

No longer forecast to breakeven

Krystal Biotech, Inc. Receives FDA Approval for the First-Ever Redosable Gene Therapy, Vyjuvek™? (Beremagenegeperpavec-Svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

No longer forecast to breakeven

Independent Director recently sold €3.1m worth of stock

Forecast breakeven date moved forward to 2024

Krystal Biotech, Inc. Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

Forecast to breakeven in 2025

Krystal Biotech, Inc. Announces New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

US Food and Drug Administration Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. Receives Fda Acceptance of Kb407 Ind Application for Cystic Fibrosis Clinical Trial

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

No longer forecast to breakeven

Krystal Biotech Announces Home Dosing in B-Vec Open Label Extension Study

Krystal Biotech, Inc., Annual General Meeting, May 20, 2022

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine

Forecast to breakeven in 2024

Krystal Biotech, Inc. Announces Board Changes

Forecast to breakeven in 2024

Lead Independent Director recently sold €6.2m worth of stock

Krystal Biotech, Inc. Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEKTM in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

Forecast to breakeven in 2023

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad